Recon Strategy
Contact

Insights

Fifteen+ years of
healthcare thinking.

Several hundred perspectives on the questions facing payers, providers, biopharma, medtech, and digital health — plus our running read on the clinical literature. Start with our sharpest work, or filter to your world.

ESSENTIAL READING

  • Biopharma, Payers, Institutional

Outcomes Based Arrangements in Biopharma

Today’s advanced therapies target devastating diseases with high unmet need. Given the urgent medical need (and pressure from patient advocates), regulators increasingly must make decisions based on early, incomplete data when it comes to durability, real-world effectiveness, and cost-effectiveness – all while bearing costs that can exceed $1 million per patient.
  • Biopharma

A few thoughts about navigating biopharma macro scenarios

Planning biopharma strategies against a robust set of macro-scenarios will be crucial to mid- and long-term success. While historically these scenarios have revolved around targeted issues, the current challengescall for a more expansive - and likely more difficult - set of questions to be asked.
  • Biopharma, Payers, Providers, Medtech, Digital

Why the Best AI Won’t Win in Healthcare

As advanced AI becomes widely accessible, healthcare companies can no longer rely on superior technology alone for lasting advantage. Instead, they need a coherent AI strategy built around five interconnected choices. Harvard Business Review article.
Sector
All
NEJM opinion

NEJM Highlights September 2015: cells, cells, cells

  • NEJM
Promise for systemic amyloidosis (and beyond?) Systemic amyloidosis is…

Read more

Can convenience care be a platform for an insurance product?

  • Payers , 
  • Providers , 
Summary A Portland-based urgent care operator is launching a health p…

Read more

NEJM Highlights August 2015: cancer and joints

  • NEJM
The emergence of a new approach to drug development in cancer Cancers…

Read more

So what if PCPs in ACO practices are not paid differently?

  • Providers
In a recent study, Ryan, Shortell, et al analyzed the composition of P…

Read more

NEJM Highlights July 2015: a first in class drug for cancer, Sovaldi cures renal failure too (sometimes), convenient primary care

  • NEJM
Palbociclib – first to target cyclin dependent kinases – breast cancer…

Read more

NEJM Highlights for June 2015: the flavor of the month is distinctly cardiovascular

  • NEJM
Interventionalist treatment for stroke: In the 80s and 90s, treatment …

Read more

NEJM Highlights May 2015: a read on ACO performance, progress in cystic fibrosis treatment, yes developing new drugs is expensive, rethinking industry-medicine relationships, CVS Caremark and smoking cessation

  • NEJM
Early results of the ACO experiment: directionally right, but impact i…

Read more

NEJM Highlights April 2015

  • NEJM
The rise, fall, and rebirth of the Chinese healthcare system A fascina…

Read more

Comparing the emerging national networks of Cleveland Clinic and Mayo Clinic

  • Providers
The build-out of the Cleveland Clinic and Mayo branded networks contin…

Read more

SELECTED ENGAGEMENTS

Insight, put to work

Our published thinking is one half of the picture. These are representative client engagements, anonymized — each tagged by sector, so you can trace the path from perspective to practice.

  • Institutional

Strategy for Statewide Health Information Exchange

A non-profit health information exchange was facing financial struggles and needed a new strategy that would keep it financially sustainable

HIE, Health IT,

  • Medtech, Early Stage

Growth strategy for point-of-care testing

Post pandemic an innovative diagnostics platform company wanted to dramatically increase its market by targeting retail clinics for its point-of-care diagnostics platform

Growth, product market fit, value proposition

  • Institutional

University Trials

Large university wanting to dramatically increase its clinical research footprint

Keep up with Recon Strategy Insights
Get an email each time we publish a new article